Prothena Corporation plc - Ordinary Shares (PRTA) News

Prothena Corporation plc - Ordinary Shares (PRTA): $32.48

0.02 (-0.06%)

POWR Rating

Component Grades








Add PRTA to Watchlist
Sign Up

Industry: Biotech




#73 of 339

in industry

Filter PRTA News Items

PRTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PRTA News Highlights

  • PRTA's 30 day story count now stands at 13.
  • Over the past 26 days, the trend for PRTA's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about PRTA are BEAT, AXSM and BMY.

Latest PRTA News From Around the Web

Below are the latest news stories about PROTHENA CORP PUBLIC LTD CO that investors may wish to consider to help them evaluate PRTA as an investment opportunity.

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.

Yahoo | November 21, 2023

FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success

Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis.

Yahoo | November 20, 2023

Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market

Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

Yahoo | November 17, 2023

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Yahoo | November 17, 2023

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.

Yahoo | November 3, 2023

Prothena Corp PLC (PRTA) Reports Q3 2023 Financial Results

Company sees net income of $21.9 million for Q3, receives $55 million payment from Bristol Myers Squibb

Yahoo | November 2, 2023

Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 246.15% and 63.68%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 2, 2023

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

DUBLIN, November 02, 2023--Prothena today reported financial results for the third quarter and first nine months of 2023 and provided business highlights

Yahoo | November 2, 2023

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 30, 2023

Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment

Biogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment.

Yahoo | October 26, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!